TODD STRATEGY GROUP

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Biopharmaceutical company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate · $60,000.00 income · posted Apr 20, 2026

Bills named in this filing 2

Lobbying activity 1

Medicare/Medicaid

Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation Act. H.R.946: ORPHAN Cures Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.